vs
SCYNEXIS INC（SCYX）与SOLAI Ltd（SLAI）财务数据对比。点击上方公司名可切换其他公司
SCYNEXIS INC的季度营收约是SOLAI Ltd的1.7倍（$18.6M vs $11.0M），SCYNEXIS INC净利率更高（65.7% vs -126.2%，领先191.9%），SCYNEXIS INC同比增速更快（1808.5% vs -43.1%）
SCYNEXIS是一家生物科技企业，专注于研发创新抗真菌疗法，用于治疗难治性真菌感染，满足未被覆盖的医疗需求，主要面向医院及专科护理市场，核心产品管线覆盖免疫低下患者等高危人群。
SCYX vs SLAI — 直观对比
营收规模更大
SCYX
是对方的1.7倍
$11.0M
营收增速更快
SCYX
高出1851.6%
-43.1%
净利率更高
SCYX
高出191.9%
-126.2%
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.6M | $11.0M |
| 净利润 | $12.3M | $-13.9M |
| 毛利率 | — | 0.1% |
| 营业利润率 | 56.3% | -126.2% |
| 净利率 | 65.7% | -126.2% |
| 营收同比 | 1808.5% | -43.1% |
| 净利润同比 | 376.5% | -173.4% |
| 每股收益（稀释后） | $0.25 | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCYXSLAI
| Q4 25 | $18.6M | — | ||
| Q3 25 | $334.0K | — | ||
| Q2 25 | $1.4M | $11.0M | ||
| Q1 25 | $257.0K | — | ||
| Q4 24 | $977.0K | — | ||
| Q3 24 | $660.0K | — | ||
| Q2 24 | $736.0K | $19.4M | ||
| Q1 24 | $1.4M | — |
净利润SCYXSLAI
| Q4 25 | $12.3M | — | ||
| Q3 25 | $-8.6M | — | ||
| Q2 25 | $-6.9M | $-13.9M | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.8M | — | ||
| Q2 24 | $-14.5M | $18.9M | ||
| Q1 24 | $411.0K | — |
毛利率SCYXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 52.4% | ||
| Q1 24 | — | — |
营业利润率SCYXSLAI
| Q4 25 | 56.3% | — | ||
| Q3 25 | -2516.5% | — | ||
| Q2 25 | -701.0% | -126.2% | ||
| Q1 25 | -3350.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1563.6% | — | ||
| Q2 24 | -1255.0% | -2.6% | ||
| Q1 24 | -692.5% | — |
净利率SCYXSLAI
| Q4 25 | 65.7% | — | ||
| Q3 25 | -2572.2% | — | ||
| Q2 25 | -504.8% | -126.2% | ||
| Q1 25 | -2097.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -425.5% | — | ||
| Q2 24 | -1964.4% | 97.9% | ||
| Q1 24 | 29.9% | — |
每股收益（稀释后）SCYXSLAI
| Q4 25 | $0.25 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.14 | $-0.01 | ||
| Q1 25 | $-0.11 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.30 | $0.02 | ||
| Q1 24 | $0.01 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.0M | $1.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $49.4M | $43.8M |
| 总资产 | $59.0M | $69.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SCYXSLAI
| Q4 25 | $40.0M | — | ||
| Q3 25 | $37.9M | — | ||
| Q2 25 | $44.8M | $1.2M | ||
| Q1 25 | $40.6M | — | ||
| Q4 24 | $59.3M | — | ||
| Q3 24 | $68.8M | — | ||
| Q2 24 | $73.0M | $2.3M | ||
| Q1 24 | $80.2M | — |
股东权益SCYXSLAI
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | — | ||
| Q2 25 | $44.5M | $43.8M | ||
| Q1 25 | $50.5M | — | ||
| Q4 24 | $55.1M | — | ||
| Q3 24 | $58.5M | — | ||
| Q2 24 | $60.4M | $45.9M | ||
| Q1 24 | $74.1M | — |
总资产SCYXSLAI
| Q4 25 | $59.0M | — | ||
| Q3 25 | $51.1M | — | ||
| Q2 25 | $60.7M | $69.1M | ||
| Q1 25 | $67.9M | — | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $99.0M | — | ||
| Q2 24 | $107.8M | $63.3M | ||
| Q1 24 | $118.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.4M | $-17.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-17.0M |
| 自由现金流率自由现金流/营收 | — | -154.2% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 1.50× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流SCYXSLAI
| Q4 25 | $18.4M | — | ||
| Q3 25 | $-8.7M | — | ||
| Q2 25 | $-7.5M | $-17.0M | ||
| Q1 25 | $-7.5M | — | ||
| Q4 24 | $-24.0M | — | ||
| Q3 24 | $765.0K | — | ||
| Q2 24 | $-10.9M | $-12.1M | ||
| Q1 24 | $-4.0M | — |
自由现金流SCYXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-17.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率SCYXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -154.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度SCYXSLAI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率SCYXSLAI
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -0.64× | ||
| Q1 24 | -9.75× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SLAI
| Data center | $6.5M | 59% |
| Cryptocurrency mining | $4.6M | 41% |
